文献速递病毒性肝炎艾滋病与性传播感染

阿片受体激动剂治疗对丙型肝炎感染保护作用的性别差异

Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究利用国际合作前瞻性队列的汇总数据,评估暴露于阿片受体激动剂治疗(OAT)的注射吸毒者(PWID)中丙型肝炎病毒(HCV)发病率的性别差异。在701名暴露于OAT的参与者中,女性HCV发病率为16.5/100人年,男性为7.6/100人年,女性调整后风险比为1.80(95%CI 1.37-2.22;结论认为女性PWID暴露于OAT后感染HCV的可能性是男性的两倍。

要点

  • 女性PWID暴露于OAT后HCV感染风险显著高于男性(aHR 1.80)。
  • 女性中非白人种族、不稳定住房、每日或更频繁注射及接受性针具共享与HCV感染相关。
  • 需要针对女性的结构性及行为干预以增强OAT预防HCV传播的效果。

核心结论

  • 暴露于OAT的女性PWID感染HCV的可能性是男性的两倍。

研究设计与样本

  • 研究使用国际合作前瞻性队列的汇总数据,采用Cox回归模型并考虑研究站点聚类效应,识别HCV感染的独立预测因素。
  • 分析纳入701名暴露于OAT的参与者,按性别进行未调整和调整的风险比(HR)及95%置信区间(CI)分析。

主要发现

  • 女性HCV发病率为16.5/100人年(95%CI 13.1-20.7),男性为7.6/100人年(95%CI 6.0-9.5)。

临床怎么用

  • 临床应关注接受OAT的女性PWID的HCV感染风险,并针对非白人种族、不稳定住房、高频注射及针具共享等可干预因素加强筛查与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While opioid agonist therapy (OAT) reduces the risk of hepatitis C virus (HCV) acquisition among people who inject drugs (PWID), protective effects may be attenuated in females. We used pooled data from an international collaboration of prospective cohorts to assess sex disparities in HCV incidence among PWID exposed to OAT. METHODS: Independent predictors of HCV infection were identified using Cox regression models with random effects after accounting for the clustering effect of study sites. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) are presented in sex-specific analyses. RESULTS: Among 701 participants exposed to OAT, HCV incidence was 16.5/100 person-years of observation (PYO) (95% CI, 13.1-20.7) in females and 7.6/100 PYO (95% CI, 6.0-9.5) in males (female:male adjusted HR [aHR], 1.80 [95% CI, 1.37-2.22]; P < .001). Factors associated with HCV acquisition among females exposed to OAT included nonwhite race (aHR, 1.79 [95% CI, 1.25-2.56]; P = .001), unstable housing (aHR, 4.00 [95% CI, 3.62-4.41]; P < .001), daily or more frequent injection (aHR, 1.45 [95% CI, 1.01-2.08]; P = .042), and receptive syringe sharing (aHR, 1.43 [95% CI, 1.33-1.53]; P < .001). CONCLUSIONS: Female PWID exposed to OAT are twice as likely as their male counterparts to acquire HCV. While there is a need for better understanding of sex differences in immune function and opioid pharmacokinetic and pharmacodynamic parameters, structural and behavioral interventions that target women are required to bolster the efficacy of OAT in preventing HCV transmission.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Geddes L, Iversen J, Wand H, et al. Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. Clin Infect Dis. 2020. PMID: 30816419. doi:10.1093/cid/ciz162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。